Epidemiologist Erin Bowles, MPH, is looking at breast cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Kaiser Permanente Breast Cancer Survivors Cohort — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of breast cancer screening and cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20+ years has provided her with expertise in data collection and quality control for many subject areas. She is also Director of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to collaborative scientists with a range of skills and expertise. She is passionate about providing long-term career paths for masters- and PhD-level scientists who don’t want to become independent investigators.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Monroy-Iglesias MJ, O'Connell K, Bhimani J, Blinder VS, Burganowski-Doud RP, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Roh JM, Sampathkumar Y, Tabatabai S, Valice E, Wang P, Aiello Bowles EJ, Bandera EV, Kushi LH, Kantor ED Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer 2026 Mar;132(5):e70294. doi: 10.1002/cncr.70294. PubMed
Kessler LG, Comstock B, Aiello Bowles EJ, Mou J, Nash MG, Bravo P, Fleckenstein LE, Pflugeisen C, Gao H, Winer RL, Ornelas IJ, Smith C, Neslund-Dudas C, Shetty P, Raghavan UG Measuring the Validity of Survey Questions on Breast, Cervical, Colorectal, and Lung Cancer Screening 2026 Feb 27 doi: 10.1093/aje/kwag040. Epub 2026-02-27. PubMed
Francis DO, Davies L, Zhang Y, Arroyo N, Fernandes-Taylor S, Nordby P, Cher BAY, Venkatesh M, Aiello Bowles EJ, Alagoz O Overdiagnosis of Papillary Thyroid Cancer 2026 Feb 2;9(2):e2559852. doi: 10.1001/jamanetworkopen.2025.59852. Epub 2026-02-02. PubMed
Gunn CM, Boyer N, Sheikh S, Lee JM, Woloshin S, Specht JM, Hubbard RA, Bowles EJA, Su YR, Tosteson ANA Patient and Physician Perspectives on Using Risk Prediction to Support Breast Cancer Surveillance Decision Making 2026 Jan;46(1):35-46 doi:10.1177/0272989X251379888. doi: 10.1177/0272989X251379888. Epub 2025-10-21. PubMed
Mann H, Dimon E, Zhang Y, Arroyo N, Adil A, Zhang Y, Alagoz O, Fernandes-Taylor S, Aiello Bowles EJ, Davies L, Francis DO Impact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017-2023) 2026 Jan;21(1):e0340347. doi: 10.1371/journal.pone.0340347. Epub 2026-01-15. PubMed
Sampathkumar Y, Zakaria Z, O'Connell K, Bhimani J, Blinder VS, Burganowski R, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Roh JM, Tabatabai S, Valice E, Bandera EV, Aiello Bowles EJ, Kushi LH, Kantor ED Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer 2025 Dec 11 doi: 10.1200/OP-25-00086. Epub 2025-12-11. PubMed
New research finds that 10% of pediatric blood and bone marrow cancers may have stemmed from radiation exposure.
New study will develop risk models to improve clinical guidelines and practice.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
The division contributes to research across the institute with methodological and subject matter expertise.
MedPage Today, March 4, 2025
How KPWHRI is contributing to better cancer screening and better outcomes for patients.